SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-163
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of November 2023
Alterity
Therapeutics Limited
(Name
of Registrant)
Level 14, 350 Collins Street,
Melbourne, Victoria 3000 Australia
(Address
of Principal Executive Office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
This
Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980
and 333-228671) and our
Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417
and 333-250076)
ALTERITY
THERAPEUTICS LIMITED
(a
development stage enterprise)
The
following exhibits are submitted:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
|
|
|
By: |
/s/ Geoffrey P. Kempler |
|
|
Geoffrey P. Kempler |
|
|
Chairman |
Date:
November 22, 2023
2
Exhibit 99.1
Alterity Therapeutics Raises $4.8M AUD in Placement
– Funds to be used primarily to
advance ongoing Phase 2 clinical trials in MSA –
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA
– 22 November 2023: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a
biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received
binding commitments for a capital raising of A$4.8M before costs via a two tranche placement (the “Placement”) of fully paid
ordinary shares (“new shares”) to Australian and international institutions and other unrelated sophisticated, professional
or other exempt investors.
“We are grateful for the support from both
current and new investors as we continue to advance our clinical development and research programs,” said David Stamler, M.D., Chief
Executive Officer of Alterity. “We are making excellent progress with our two Phase 2 clinical trials in Multiple System Atrophy
with enrollment recently completed in our randomized, double-blind ATH434-201 study. In our ATH434-202 open label biomarker study, we
look forward to potential preliminary data in the first half of next year in the first cohort of patients from that trial.”
Placement details
The Placement was conducted at A$0.0035 per new
share. For every new share issued, one (1) free attaching short-dated option will be issued. The short-dated option will have an exercise
price of A$0.007 and an expiry date of 31 August 2024. In addition, for every three (3) new shares issued, one (1) free attaching long-dated
option will be issued. The long-dated option will have an exercise price of A$0.01 and an expiry date of 31 August 2026.
Tranche one of the Placement is to raise approximately
A$1.3M and will be issued under the Company’s available placement capacity pursuant to ASX Listing Rule 7.1 (362,462,762 new shares).
The issue of new shares forming tranche one of the Placement is proposed to occur on or about 29 November 2023.
Tranche two of the Placement is to raise approximately
A$3.5M (1,008,965,809 new shares) and the issue of all free attaching short-dated options (1,371,428,571 short-dated options) and long-dated
options (457,142,857 long-dated options) are conditional on shareholder approval to be sought at a General Meeting of the Company which
is planned for late December 2023/early January 2024. Subject to satisfying the quotation conditions of ASX, including the spread requirements
set out in ASX Listing Rule 2.5, condition 6, the long-dated options are intended to be quoted on the ASX on completion of the SPP.
The New Shares and New Options under Tranche two
of the Placement include an aggregate of A$100,000 of commitments from related parties (directors and their associates) to subscribe under
the Placement, subject to shareholder approval which will be sought at the same general meeting. The Company CEO, David Stamler (or his
nominee(s)), has also committed to subscribe under the Placement.
The new shares to be issued will rank equally
with existing ATH fully paid ordinary shares.
Security Purchase Plan
The Company is also pleased to provide shareholders
with a registered address in Australia and New Zealand at the record date (7.00pm on 21 November 2023) with the opportunity to participate
in a Security Purchase Plan (“SPP”) under which shares and free-attaching options are to be offered to eligible shareholders
on the same terms as the Placement up to a maximum of A$30,000 per eligible shareholder. The maximum total subscription under the SPP
is A$2 million.
The SPP offer is only being made to shareholders
with a registered address in Australia or New Zealand in the register of members of the Company, having regard to the compliance costs
of making the SPP offer in other jurisdictions.
The Company will release offer materials for the
SPP after and subject to shareholder approval.
Use of Proceeds
The use of proceeds from this financing will provide
ongoing funding of Alterity’s Phase 2 clinical trials in MSA, ATH434-201 and ATH434-202, along with planning for a potential Phase
3 clinical trial in MSA, continuing discovery and research efforts in neurodegenerative diseases, including Parkinson’s Disease,
and general working capital.
Alterity’s lead candidate, ATH434, is an
oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically
to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone,
it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as MSA. ATH434 successfully
completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal
models of MSA.
Study ATH434-201 is a randomized, double-blind,
placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial
in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European
Commission.
Alterity is also evaluating ATH434 in preclinical
studies in Parkinson’s disease with recent publications that have provided further evidence that ATH434 has the potential to be
neuroprotective in humans with this condition. The Company also maintains a robust discovery and research efforts focused on generating
novel, patentable compounds covering several neurodegenerative diseases.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology
company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset,
ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple
System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology
of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please
visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO
of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934.
The Company has tried to identify such forward-looking statements by use of such words as “expects,” “intends,” “hopes,”
“anticipates,” “believes,” “could,” “may,” “evidences” and “estimates,” and
other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause
actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk
Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on
Form 6-K, including, but not limited to the following: statements relating to the Company’s drug development program, including, but not
limited to the initiation, progress and outcomes of clinical trials of the Company’s drug development program, including, but not limited
to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval,
production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to
procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug
compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent
protection for the Company’s intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent
rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made
by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
Not an offer in the United States
This announcement does not constitute
an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described
in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in
the United States or to US Persons (as defined in Rule 902(k) under the US Securities Act) except in transactions exempt from, or not
subject to, the registration requirements of the US Securities Act and applicable US state securities laws.
3
Alterity Therapeutics (PK) (USOTC:PRNAF)
過去 株価チャート
から 8 2024 まで 9 2024
Alterity Therapeutics (PK) (USOTC:PRNAF)
過去 株価チャート
から 9 2023 まで 9 2024